Want to see MNKD full AI Analyst Report?
MNKD Stock Chart & Stats
$4.09
-$0.08(-1.82%)
At close: 4:00 PM EDT
$4.09
-$0.08(-1.82%)
Day’s Range― - ―
52-Week Range$2.23 - $6.51
Previous CloseN/A
Volume958.79K
Average Volume (3M)4.89M
Market Cap
$977.50M
Enterprise Value$1.64B
Total Cash (Recent Filing)$111.13M
Total Debt (Recent Filing)$330.85M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 10, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding321,544,500
10 Day Avg. Volume4,570,429
30 Day Avg. Volume4,893,764
Financial Highlights & Ratios
PEG Ratio-3.54
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market Cap1.68
Enterprise Value/Revenue4.17
Enterprise Value/Gross Profit5.51
Enterprise Value/Ebitda54.50
Forecast
1Y Price Target
$7.56Price Target Upside84.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$444.73M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginThe sustained revenue ramp indicates expanding commercial traction across MannKind’s business, while the high gross margin suggests attractive product economics. Together, these factors provide a foundation for reinvestment and potential operating leverage as the company scales its commercial portfolio.
Diversified Inhaled-Product PlatformMannKind combines commercial products with a proprietary inhaled-drug platform and manufacturing capabilities. This creates multiple avenues for growth through its own products, partnered programs, and potential future licensing, reducing reliance on a single development or revenue opportunity.
Recent Financing Supports LiquidityThe completed financing added near-term liquidity and enabled MannKind to address a substantial milestone obligation associated with an FDA approval. This supports business continuity and gives management greater capacity to fund operations and commercial priorities over the coming months.
Bears Say
Negative Equity And Elevated DebtNegative equity leaves MannKind with a limited balance-sheet cushion, while elevated debt increases financial risk and reduces flexibility. If operating performance weakens, the company may have fewer internal resources available to absorb pressure or fund strategic initiatives.
Return To Free-Cash-Flow BurnThe reversal from positive annual free cash flow to substantial TTM cash burn indicates that cash generation is not yet dependable. Continued burn would increase pressure on liquidity and make disciplined working-capital management and funding access more important to sustaining growth.
Unstable ProfitabilityStrong revenue and gross margin have not yet translated into consistent bottom-line earnings. The return to a sizable net loss and thin operating margin suggests that operating expenses and other costs remain significant, limiting the durability of current earnings power.
MannKind News
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $2.23 and its highest was $6.51 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is $977.50M.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is Nov 10, 2026 which is in 23 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Aug 05, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.008 by -$0.052.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is -0.06.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 321,544,500 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.008. Following the earnings report the stock price went down -5.122%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.56 (84.81% Upside)
$7.56 (84.81% Upside)
Blogger Sentiment
Neutral
MNKD Sentiment 56%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 867.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 11.9%
Last 30 Days ▼ 11.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.17%
12-Months-Change
Fundamentals
Return on Equity
78.60%
Trailing 12-Months
Asset Growth
77.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mannkind Corp.
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple near-term commercial and clinical catalysts, solid top-line growth (15% YoY) and strong operational wins (FURO6 prescriber growth, royalties up 9%, SC Pharma synergies exceeding $20M), alongside meaningful progress on pipeline programs (MNKD-201 Phase 1b and Phase 2 start) and an expanded collaboration with United Therapeutics (ralinepag DPI payment and milestone potential). Short-term challenges include seasonality, field reorganization and inventory transitions that pressured Q1 revenue and contributed to GAAP and non-GAAP losses, plus some formulation and development uncertainty for new DPI programs. Management reiterated full-year FURO6 guidance and expects acceleration in H2 tied to the ReadyFlow auto-injector and Afrezza pediatrics launch, indicating confidence that near-term investments will drive longer-term growth.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$7.56
▲(84.81% Upside)
Technical Analysis
Ownership Overview
2.24% Insiders
9.74% Mutual Funds
1.58% Other Institutional Investors
71.25% Public Companies and
Individual Investors